DE60327640D1 - - Google Patents
Info
- Publication number
- DE60327640D1 DE60327640D1 DE60327640T DE60327640T DE60327640D1 DE 60327640 D1 DE60327640 D1 DE 60327640D1 DE 60327640 T DE60327640 T DE 60327640T DE 60327640 T DE60327640 T DE 60327640T DE 60327640 D1 DE60327640 D1 DE 60327640D1
- Authority
- DE
- Germany
- Prior art keywords
- faah
- competitive inhibitors
- alpha
- heterocyclic pharmacophore
- binding subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031975 WO2004033652A2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60327640D1 true DE60327640D1 (ru) | 2009-06-25 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60327640T Expired - Lifetime DE60327640D1 (ru) | 2002-10-08 | 2003-10-08 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (ru) |
| EP (2) | EP2093220A3 (ru) |
| JP (1) | JP4628789B2 (ru) |
| KR (1) | KR20050070041A (ru) |
| CN (1) | CN1703407A (ru) |
| AT (1) | ATE431342T1 (ru) |
| AU (1) | AU2003275493A1 (ru) |
| BR (1) | BR0314980A (ru) |
| CA (1) | CA2501575A1 (ru) |
| DE (1) | DE60327640D1 (ru) |
| EA (1) | EA008767B1 (ru) |
| ES (1) | ES2325686T3 (ru) |
| MX (1) | MXPA05003762A (ru) |
| WO (1) | WO2004033652A2 (ru) |
| ZA (1) | ZA200501837B (ru) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| WO2006044617A1 (en) * | 2004-10-15 | 2006-04-27 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| EP2937341B1 (en) | 2004-12-30 | 2017-07-05 | Janssen Pharmaceutica N.V. | 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
| PE20070099A1 (es) | 2005-06-30 | 2007-02-06 | Janssen Pharmaceutica Nv | N-heteroarilpiperazinil ureas como moduladores de la amida hidrolasa del acido graso |
| US20090111778A1 (en) | 2005-11-18 | 2009-04-30 | Richard Apodaca | 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase |
| AU2007217813A1 (en) * | 2006-02-17 | 2007-08-30 | The Scripps Research Institute | Oxazole ketones as modulators of fatty acid amide hydrolase |
| CA2658887C (en) * | 2006-07-28 | 2016-08-23 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| JP2010502711A (ja) * | 2006-09-08 | 2010-01-28 | ザ スクリプス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼの置換オキサゾールケトンモジュレーター |
| WO2008147553A1 (en) * | 2007-05-25 | 2008-12-04 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| JP2010533645A (ja) * | 2007-05-31 | 2010-10-28 | ザ スクリプス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼの三環系阻害剤 |
| US8598202B2 (en) * | 2008-02-19 | 2013-12-03 | Janssen Pharmaceutica Nv | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| WO2009154785A2 (en) * | 2008-06-19 | 2009-12-23 | The Scripps Research Institute | C4-substituted alpha-keto oxazoles |
| US8987312B2 (en) | 2008-07-09 | 2015-03-24 | The Scripps Research Institute | Alpha-keto heterocycles as FAAH inhibitors |
| MX2011001313A (es) | 2008-08-04 | 2011-03-04 | Merck Sharp & Dohme | Derivados de oxazol utiles como inhibidores de la amida hidrolasa de acidos grasos. |
| WO2010068452A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| AU2009330821B2 (en) * | 2008-12-24 | 2015-06-11 | Bial - Portela & Ca, S.A. | Pharmaceutical compounds |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| WO2011030798A1 (ja) | 2009-09-09 | 2011-03-17 | 大日本住友製薬株式会社 | ８－オキソジヒドロプリン誘導体 |
| CN102647984B (zh) * | 2009-10-02 | 2015-03-25 | 埃维克辛公司 | 抗炎症的2-羰基噻唑和2-羰基恶唑 |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| RU2012136624A (ru) * | 2010-01-28 | 2014-03-10 | Мерк Шарп Энд Домэ Корп. | Фармацевтические композиции для лечения боли и других показаний |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| ES2888231T3 (es) * | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| CN104244948B (zh) * | 2012-02-17 | 2016-11-16 | 爱普泰克集团有限公司 | 在炎症性疾病的治疗中使用的用于调节n-酰基乙醇胺的特异性酰胺酶的组合物和方法 |
| CN105102438B (zh) | 2013-01-29 | 2019-04-30 | 埃维克辛公司 | 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物 |
| EP3063144B1 (en) | 2013-11-01 | 2021-09-08 | Boehringer Ingelheim Animal Health USA Inc. | Antiparasitic and pesticidal isoxazoline compounds |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| WO2016160168A1 (en) * | 2015-02-20 | 2016-10-06 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| JP2018513153A (ja) | 2015-04-24 | 2018-05-24 | オメロス コーポレーション | Ｐｄｅ１０インヒビターならびに関連する組成物および方法 |
| EP3095787A1 (en) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmaceutically active compounds as dag-lipase inhibitors |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5821370A (en) * | 1994-10-24 | 1998-10-13 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) * | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| AU2003275493A1 (en) | 2002-10-08 | 2004-05-04 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
-
2003
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 EP EP09006391A patent/EP2093220A3/en not_active Withdrawn
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
- 2003-10-08 EP EP03759771A patent/EP1549624B1/en not_active Expired - Lifetime
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Application Discontinuation
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en active Application Filing
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0314980A (pt) | 2005-08-09 |
| EP1549624A4 (en) | 2006-09-20 |
| AU2003275493A1 (en) | 2004-05-04 |
| JP4628789B2 (ja) | 2011-02-09 |
| EP1549624B1 (en) | 2009-05-13 |
| EA008767B1 (ru) | 2007-08-31 |
| EP1549624A2 (en) | 2005-07-06 |
| KR20050070041A (ko) | 2005-07-05 |
| ZA200501837B (en) | 2006-06-28 |
| ATE431342T1 (de) | 2009-05-15 |
| MXPA05003762A (es) | 2005-07-22 |
| CA2501575A1 (en) | 2004-04-22 |
| US7662971B2 (en) | 2010-02-16 |
| WO2004033652A2 (en) | 2004-04-22 |
| EP2093220A3 (en) | 2009-11-11 |
| JP2006502229A (ja) | 2006-01-19 |
| US20060111359A1 (en) | 2006-05-25 |
| WO2004033652A3 (en) | 2004-09-16 |
| ES2325686T3 (es) | 2009-09-14 |
| EA200500633A1 (ru) | 2005-10-27 |
| EP2093220A2 (en) | 2009-08-26 |
| CN1703407A (zh) | 2005-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60327640D1 (ru) | ||
| CO5251452A1 (es) | Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar | |
| NO2015002I1 (no) | Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav | |
| NO20064418L (no) | Nye amido-substituerte hydroksy-6-fenylfenantridiner | |
| AP2006003633A0 (en) | Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity | |
| SI2937341T1 (sl) | Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj | |
| SG155222A1 (en) | Thiazole based inhibitors of atp-utilizing enzymes | |
| IL236013A0 (en) | Adamantyl acetamide derivatives as 11-beta-hydroxysteroid dehydrogenase type 1 enzyme inhibitors | |
| HK1105864A1 (en) | Heterocyclic compounds which are active as inhibitors of beta-lactamases | |
| LU92555I2 (fr) | Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol | |
| IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
| ATE304003T1 (de) | Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren | |
| ZA200501532B (en) | Substituted (thiazol-2-YL)-amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes | |
| NO20020770D0 (no) | Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av fedme | |
| AU2003229772A1 (en) | Derivatives of 2-(1-benzyl-1h-pyrazolo (3, 4-b)pyridine-3yl) -5-(4-pyridinyl)-4-pyrimidine amine and the use thereof as guanylate cyclase stimulators | |
| PL1685142T3 (pl) | Pochodne kwasu fosfinowego, inhibitory beta-sekterazy do leczenia choroby Alzheimera | |
| AP2005003220A0 (en) | Novel polymorph of N-Methyl-N-(3-{3-[2-Thienylcarbonyl]-Pyrazol-[1,5-Alpha]-Pyrimidin-7-YI}Phenyl) Acetanide and compositions and methods related thereto. | |
| HUP0100935A2 (hu) | Amidvegyületet tartalmazó, szinergetikus hatású fungicid hatóanyag-keverék és alkalmazása | |
| EP1616866A4 (en) | M-STAGE kinesin inhibitor | |
| PL371439A1 (en) | Phthalimido derivatives as inhibitors of monoamine oxidase b | |
| MXPA05011855A (es) | 1,2-diarilimidazoles utiles como inhibidores de ciclooxigenasa. | |
| CA2479353A1 (en) | N-substituted benzothiophenesulfonamide derivative | |
| WO2005011598A3 (en) | Leukemia treatment method and composition | |
| RS20050181A (en) | Novel benzonaphthyridines | |
| MA30708B1 (fr) | Composes de 2-amido-4-isoxazolyl thiazole presentant une activite inhibitrice d'une enzyme utilisant l'atp et compositions et utilisation desdits composes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |